APC anti-mouse IFN-γ Antibody

Pricing & Availability
Clone
XMG1.2 (See other available formats)
Regulatory Status
RUO
Other Names
Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype
Rat IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
XMG1dot2_APC_032808
PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
  • XMG1dot2_APC_032808
    PMA/Ionomycin-stimulated (6hrs) C57BL/6 mouse splenocytes stained with XMG1.2 APC and B220 (RA3-6B2) PE
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
505809 25 µg 36€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
505810 100 µg 106€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  3. Cignarella F et al. 2018. Cell metabolism. 27(6):1222-1235 . PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Chinta KC et al. 2018. Cell reports. 25(7):1938-1952 . PubMed
  6. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  7. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  8. Kisielow J, et al. 2019. Nat Immunol. 1.286111111. PubMed
  9. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  10. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  11. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  12. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  13. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  14. Bergot AS, et al. 2020. J Immunol. 204:1787. PubMed
  15. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  16. Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
  17. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  18. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  19. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  20. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  21. Suresh R, et al. 2020. J Immunother Cancer. 8:. PubMed
  22. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  23. Muthumani K, et al. 2015. Sci Transl Med. 7: 301ra132. PubMed
  24. Laroche-Lefebvre C, et al. 2016. J Immunol. 197: 3618 - 3627. PubMed
  25. Sanchez-Felipe L, et al. 2021. Nature. 590:320. PubMed
  26. Yang C, et al. 2018. J Immunol. 200:1316. PubMed
  27. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  28. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  29. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  30. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  31. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  32. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  33. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  34. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  35. Zhao Y, et al. 2015. PLoS One. 10: 0134797. PubMed
  36. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  37. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  38. Ron–Harel N, et al. 2019. Cell Rep. 28:3011. PubMed
  39. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  40. Lu J, et al. 2018. ACS Nano. 12:11041. PubMed
  41. Diao L, et al. 2022. iScience. 25:105511. PubMed
  42. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  43. Gu M, et al. 2021. Nat Immunol. 22:193. PubMed
  44. Yang X, et al. 2021. Front Pharmacol. 12:771046. PubMed
  45. Rao E, et al. 2021. Sci Immunol. 6:. PubMed
  46. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  47. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  48. Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed
  49. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  50. Nagaoka M, et al. 2014. J Immunol. 193:2812. PubMed
  51. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  52. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  53. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  54. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  55. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  56. Saini V, et al. 2020. Nat Commun. 0.845138889. PubMed
  57. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  58. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  59. Konrath KM, et al. 2022. Cell Rep. 38:110318. PubMed
  60. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  61. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  62. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  63. Cabrera-Mora M, et al. 2015. Infect Immun . 83: 3749-3761. PubMed
  64. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  65. Cao W, et al. 2017. Immunity. 47:1182. PubMed
  66. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  67. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  68. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  69. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  70. Hilpert C, et al. 2016. J Immunol. 197: 2780 - 2786. PubMed
  71. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  72. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  73. Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed
  74. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  75. Lai C, et al. 2009. Invest Ophthalmol Vis Sci. 50:4279. PubMed
  76. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  77. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  78. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  79. Mills C, et al. 2022. Cells. 11:. PubMed
  80. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  81. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  82. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  83. Marks KE, et al. 2021. Cell Reports. 35(13):109303. PubMed
  84. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  85. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  86. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  87. Harty J 2009. Infect Immun. 77:1894. PubMed
  88. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  89. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  90. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  91. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  92. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  93. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  94. Fatkhullina AR et al. 2018. Immunity. 49(5):943-957 . PubMed
  95. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  96. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  97. Bhattacharya D, et al. 2014. J Biol Chem. 289:16508. PubMed
  98. El-Zaatari M, et al. 2014. J Immunol. 193:807. PubMed
  99. Souza COS, et al. 2021. iScience. 24(6):102548. PubMed
  100. Peng Y 2017. PLoS One. 10.1371/journal.pone.0188112. PubMed
  101. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  102. Sinclair LV et al. 2019. Elife. 8 pii: e44210. PubMed
  103. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  104. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  105. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  106. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  107. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  108. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  109. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  110. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  111. Ouyang W, et al. 2021. Invest Ophthalmol Vis Sci. 62:25:00. PubMed
  112. Baban B, et al. 2021. JCI Insight. 6:00. PubMed
  113. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  114. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  115. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  116. Park JY, et al. 2019. Cell Rep. 27:2548. PubMed
  117. Malik A et al. 2018. Immunity. 49(3):515-530 . PubMed
  118. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
  119. Yong L, et al. 2022. Nat Commun. 13:4255. PubMed
  120. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  121. Yuan Y, et al. 2022. Cell Rep. 38:110256. PubMed
  122. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  123. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  124. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  125. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  126. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  127. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  128. Huang F, et al. 2018. Oncoimmunology. 7:e1450713. PubMed
  129. Levesque S, et al. 2019. Oncoimmunology. 8:e1657375. PubMed
  130. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  131. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  132. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  133. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  134. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  135. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  136. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  137. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  138. Tonkin D, et al. 2008. J Immunol. 181:4516. PubMed
  139. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  140. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  141. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  142. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  143. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  144. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  145. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  146. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  147. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  148. Dudeck J, et al. 2019. J Allergy Clin Immunol. 143:1849. PubMed
  149. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  150. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  151. Pandit M, et al. 2021. Eur J Immunol. 51:1461. PubMed
  152. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  153. Derada Troletti C, et al. 2021. Cell Reports. 35(9):109201. PubMed
  154. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  155. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  156. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  157. Jin R, et al. 2008. J Immunol. 180:2256. PubMed
  158. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  159. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
  160. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  161. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  162. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  163. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  164. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  165. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  166. Gupta S, et al. 2022. Life Sci. 288:120182. PubMed
  167. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  168. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  169. M H, et al. 2016. Open Bio. 6: 150208. PubMed
  170. Moon J, et al. 2020. Immune Netw. 20:e40. PubMed
  171. Fang Y, et al. 2021. J Clin Invest. 131:00:00. PubMed
  172. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  173. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  174. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  175. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  176. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  177. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  178. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  179. Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed
  180. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  181. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  182. Kurihara T, et al. 2015. PLoS One. 10: e0139692. PubMed
  183. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  184. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  185. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  186. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  187. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  188. Byrne K, et al. 2014. J Immunol. 192:1433. PubMed
  189. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  190. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  191. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  192. Okuyama Y, et al. 2020. FASEB J. 540:34. PubMed
  193. Sparber F, et al. 2019. Cell Host Microbe. 25:389. PubMed
  194. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  195. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  196. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  197. Neckermann P, et al. 2021. Front Immunol. 12:761214. PubMed
  198. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  199. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  200. Sheng J, et al. 2021. eLife. 10:00. PubMed
  201. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  202. Bransi A, et al. 2015. Cancer Immunol Res. 3: 1279 - 1288. PubMed
  203. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  204. Kwak JE, et al. 2019. Nat Commun. 10:3836. PubMed
  205. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  206. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  207. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  208. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  209. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  210. Yang N, et al. 2021. NPJ Precis Oncol. 5:37. PubMed
  211. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  212. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  213. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
  214. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  215. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  216. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  217. Yang L, et al. 2021. Front Immunol. 12:722273. PubMed
  218. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  219. Tang L, et al. 2022. Front Immunol. 12:770402. PubMed
  220. Jackson C, et al. 2016. Clin Cancer Res. 22: 1161 - 1172. PubMed
  221. Muri J, et al. 2020. Cell Reports. 30(13):4399-4417. PubMed
  222. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  223. Kalim KW, et al. 2021. Front Immunol. 12:726393. PubMed
  224. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  225. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  226. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
RRID
AB_315403 (BioLegend Cat. No. 505809)
AB_315404 (BioLegend Cat. No. 505810)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse IFN-γ

  • Biotin anti-mouse IFN-γ

  • FITC anti-mouse IFN-γ

  • PE anti-mouse IFN-γ

  • Purified anti-mouse IFN-γ

  • Alexa Fluor® 488 anti-mouse IFN-γ

  • Alexa Fluor® 647 anti-mouse IFN-γ

  • Pacific Blue™ anti-mouse IFN-γ

  • PerCP/Cyanine5.5 anti-mouse IFN-γ

  • PE/Cyanine7 anti-mouse IFN-γ

  • Brilliant Violet 421™ anti-mouse IFN-γ

  • Brilliant Violet 650™ anti-mouse IFN-γ

  • Ultra-LEAF™ Purified anti-mouse IFN-γ

  • Brilliant Violet 711™ anti-mouse IFN-γ

  • Brilliant Violet 785™ anti-mouse IFN-γ

  • Brilliant Violet 605™ anti-mouse IFN-γ

  • Brilliant Violet 510™ anti-mouse IFN-γ

  • Purified anti-mouse IFN-γ (Maxpar® Ready)

  • PE/Dazzle™ 594 anti-mouse IFN-γ

  • Alexa Fluor® 700 anti-mouse IFN-γ

  • APC/Cyanine7 anti-mouse IFN-γ

  • GoInVivo™ Purified anti-mouse IFN-γ

  • APC/Fire™ 750 anti-mouse IFN-γ

  • Spark NIR™ 685 anti-mouse IFN-γ

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account